Padi A, Pericot-Valverde I, Heo M, Dotherow J, Niu J, Martin M
Viruses. 2024; 16(8.
PMID: 39205278
PMC: 11359142.
DOI: 10.3390/v16081304.
Chien C, Chou T, Chen L, Lin C, Chang J, Liu C
Microorganisms. 2024; 12(7).
PMID: 39065170
PMC: 11279112.
DOI: 10.3390/microorganisms12071402.
Saich F, Walker S, Hellard M, Stoove M, Seear K
Public Health Ethics. 2024; 17(1-2):40-52.
PMID: 39005529
PMC: 11245707.
DOI: 10.1093/phe/phae006.
Fontaine G, Presseau J, Bruneau J, Etherington C, Thomas I, Hung J
Int J Equity Health. 2024; 23(1):124.
PMID: 38886803
PMC: 11184812.
DOI: 10.1186/s12939-024-02209-0.
Dawe J, Gorton C, Lewis R, Richmond J, Wilkinson A, Pedrana A
Viruses. 2024; 16(5).
PMID: 38793681
PMC: 11125761.
DOI: 10.3390/v16050800.
Implementation of a mobile health clinic framework for Hepatitis C virus screening and treatment: a descriptive study.
Rennert L, Howard K, Kickham C, Gezer F, Coleman A, Roth P
Lancet Reg Health Am. 2023; 29:100648.
PMID: 38124995
PMC: 10733089.
DOI: 10.1016/j.lana.2023.100648.
Hepatitis C Treatment Uptake Following Dried Blood Spot Testing for Hepatitis C RNA in New South Wales, Australia: The NSW DBS Pilot Study.
Conway A, Stevens A, Murray C, Prain B, Power C, McNulty A
Open Forum Infect Dis. 2023; 10(11):ofad517.
PMID: 38023551
PMC: 10665037.
DOI: 10.1093/ofid/ofad517.
Returning incidentally discovered Hepatitis C RNA-seq results to COPDGene study participants.
Silverman E, Kim A, Make B, Regan E, Morrow J, Hersh C
NPJ Genom Med. 2023; 8(1):36.
PMID: 37903807
PMC: 10616181.
DOI: 10.1038/s41525-023-00379-4.
Facilitated telemedicine for hepatitis C virus: Addressing challenges for improving health and life for people with opioid use disorder.
Talal A, Jaanimagi U, Dharia A, Dickerson S
Health Expect. 2023; 26(6):2594-2607.
PMID: 37641398
PMC: 10632612.
DOI: 10.1111/hex.13854.
Rapid hepatitis C virus point-of-care RNA testing and treatment at an integrated supervised consumption service in Toronto, Canada: a prospective, observational cohort study.
Lettner B, Mason K, Greenwald Z, Broad J, Mandel E, Feld J
Lancet Reg Health Am. 2023; 22:100490.
PMID: 37388709
PMC: 10300568.
DOI: 10.1016/j.lana.2023.100490.
Human Immunodeficiency Virus and Hepatitis C Virus-related Disparities in Undergoing Emergency General Surgical Procedures in the United States, 2016-2019.
Himmelstein K, Afif I, Beard J, Tsai A
Ann Surg. 2023; 279(2):240-245.
PMID: 37226805
PMC: 10674045.
DOI: 10.1097/SLA.0000000000005918.
Social determinants of health derived from people with opioid use disorder: Improving data collection, integration and use with cross-domain collaboration and reproducible, data-centric, notebook-style workflows.
Markatou M, Kennedy O, Brachmann M, Mukhopadhyay R, Dharia A, Talal A
Front Med (Lausanne). 2023; 10:1076794.
PMID: 36936205
PMC: 10017859.
DOI: 10.3389/fmed.2023.1076794.
How the rural risk environment underpins hepatitis C risk: Qualitative findings from rural southern Illinois, United States.
Walters S, Frank D, Felsher M, Jaiswal J, Fletcher S, Bennett A
Int J Drug Policy. 2023; 112:103930.
PMID: 36641816
PMC: 9974910.
DOI: 10.1016/j.drugpo.2022.103930.
Integrated hepatitis C treatment is associated with improved retention and success in outpatient treatment for opioid use disorder at a private clinic.
Losikoff P, Bosse J, Martin S, Wilson A, Chiodo L
Front Psychiatry. 2022; 13:932306.
PMID: 36186876
PMC: 9515307.
DOI: 10.3389/fpsyt.2022.932306.
Optimising community health services in Australia for populations affected by stigmatised infections: What do service users want?.
Horwitz R, Brener L, Marshall A, Caruana T, Newman C
Health Soc Care Community. 2022; 30(6):e3686-e3695.
PMID: 36181284
PMC: 10092471.
DOI: 10.1111/hsc.14037.
Integrating Hepatitis C Care for Opioid Substitution Treatment Patients Attending General Practice: Feasibility, Clinical, and Cost-Effectiveness Analysis.
McCombe G, Swan D, Lambert J, OConnor E, Ward Z, Vickerman P
Interact J Med Res. 2022; 11(2):e35300.
PMID: 35998029
PMC: 9449831.
DOI: 10.2196/35300.
Transformation of identity in substance use as a pathway to recovery and the potential of treatment for hepatitis C: a systematic review.
Donaldson S, Radley A, Dillon J
Addiction. 2022; 118(3):425-437.
PMID: 35993427
PMC: 10087584.
DOI: 10.1111/add.16031.
Impact of comprehensive care on health care use among a cohort of marginalized people living with hepatitis C in Toronto.
Mandel E, Kendall C, Mason K, Guyton M, Lettner B, Broad J
Can Liver J. 2022; 3(2):203-211.
PMID: 35991859
PMC: 9202786.
DOI: 10.3138/canlivj.2019-0021.
The role of prevention strategies in achieving HCV elimination in Canada: what are the remaining challenges?.
Hoj S, Minoyan N, Artenie A, Grebely J, Bruneau J
Can Liver J. 2022; 1(2):4-13.
PMID: 35990720
PMC: 9202798.
DOI: 10.3138/canlivj.1.2.003.
Characterizing risk behaviour and reinfection rates for successful programs to engage core transmitters in HCV elimination (C-RESPECT).
Conway B, Smyth D, Thomas R, Wong A, Sebastiani G, Cooper C
Can Liver J. 2022; 4(4):346-359.
PMID: 35989890
PMC: 9235128.
DOI: 10.3138/canlivj-2021-0005.